162 related articles for article (PubMed ID: 32320427)
1. The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy.
Fabre MS; Stanton NM; Slatter TL; Lee S; Senanayake D; Gordon RMA; Castro ML; Rowe MR; Taha A; Royds JA; Hung N; Melnick AM; McConnell MJ
PLoS One; 2020; 15(4):e0231470. PubMed ID: 32320427
[TBL] [Abstract][Full Text] [Related]
2. BCL6 promotes glioma and serves as a therapeutic target.
Xu L; Chen Y; Dutra-Clarke M; Mayakonda A; Hazawa M; Savinoff SE; Doan N; Said JW; Yong WH; Watkins A; Yang H; Ding LW; Jiang YY; Tyner JW; Ching J; Kovalik JP; Madan V; Chan SL; Müschen M; Breunig JJ; Lin DC; Koeffler HP
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3981-3986. PubMed ID: 28356518
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway.
Song W; Wang Z; Kan P; Ma Z; Wang Y; Wu Q; Yao X; Zhang B
Biomed Res Int; 2018; 2018():6953506. PubMed ID: 30420967
[TBL] [Abstract][Full Text] [Related]
4. MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR/BCL6/p53 axis.
Srivastava S; Makala H; Sharma V; Suri V; Sarkar C; Kulshreshtha R
Cell Mol Life Sci; 2022 Jan; 79(2):104. PubMed ID: 35091793
[TBL] [Abstract][Full Text] [Related]
5. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of B-cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response.
Tahara K; Takizawa M; Yamane A; Osaki Y; Ishizaki T; Mitsui T; Yokohama A; Saitoh T; Tsukamoto N; Matsumoto M; Murakami H; Nojima Y; Handa H
Cancer Sci; 2017 Aug; 108(8):1556-1564. PubMed ID: 28544233
[TBL] [Abstract][Full Text] [Related]
7. Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.
Wu WR; Lin JT; Pan CT; Chan TC; Liu CL; Wu WJ; Sheu JJ; Yeh BW; Huang SK; Jhung JY; Hsiao MS; Li CF; Shiue YL
Theranostics; 2020; 10(2):707-724. PubMed ID: 31903146
[TBL] [Abstract][Full Text] [Related]
8. Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells.
Ujvari D; Nagy N; Madapura HS; Kallas T; Kröhnke MCL; Stenke L; Klein E; Salamon D
Biochem Biophys Res Commun; 2018 Apr; 498(3):502-508. PubMed ID: 29510136
[TBL] [Abstract][Full Text] [Related]
9. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
10. The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress.
Liu Y; Feng J; Yuan K; Wu Z; Hu L; Lu Y; Li K; Guo J; Chen J; Ma C; Pang X
Elife; 2022 May; 11():. PubMed ID: 35503721
[TBL] [Abstract][Full Text] [Related]
11. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Yang CH; Wang Y; Sims M; Cai C; He P; Yue J; Cheng J; Boop FA; Pfeffer SR; Pfeffer LM
Oncotarget; 2016 Dec; 7(51):84017-84029. PubMed ID: 27705947
[TBL] [Abstract][Full Text] [Related]
12. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
13. DNA damage-induced NF-κB activation in human glioblastoma cells promotes miR-181b expression and cell proliferation.
Xu RX; Liu RY; Wu CM; Zhao YS; Li Y; Yao YQ; Xu YH
Cell Physiol Biochem; 2015; 35(3):913-25. PubMed ID: 25633526
[TBL] [Abstract][Full Text] [Related]
14. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH
Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175
[TBL] [Abstract][Full Text] [Related]
15. BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.
Peng C; Hu Q; Yang F; Zhang H; Li F; Huang C
J Immunol; 2019 Feb; 202(3):704-713. PubMed ID: 30567732
[TBL] [Abstract][Full Text] [Related]
16. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
17. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
Jardin F; Ruminy P; Bastard C; Tilly H
Pathol Biol (Paris); 2007 Feb; 55(1):73-83. PubMed ID: 16815642
[TBL] [Abstract][Full Text] [Related]
18. The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma.
Shi Y; Kuai Y; Lei L; Weng Y; Berberich-Siebelt F; Zhang X; Wang J; Zhou Y; Jiang X; Ren G; Pan H; Mao Z; Zhou R
Oncotarget; 2016 Nov; 7(47):77444-77456. PubMed ID: 27764808
[TBL] [Abstract][Full Text] [Related]
19. BCL6 is critical for the development of a diverse primary B cell repertoire.
Duy C; Yu JJ; Nahar R; Swaminathan S; Kweon SM; Polo JM; Valls E; Klemm L; Shojaee S; Cerchietti L; Schuh W; Jäck HM; Hurtz C; Ramezani-Rad P; Herzog S; Jumaa H; Koeffler HP; de Alborán IM; Melnick AM; Ye BH; Müschen M
J Exp Med; 2010 Jun; 207(6):1209-21. PubMed ID: 20498019
[TBL] [Abstract][Full Text] [Related]
20. The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death.
He Y; Roos WP; Wu Q; Hofmann TG; Kaina B
Mol Cancer Res; 2019 May; 17(5):1129-1141. PubMed ID: 30796178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
